A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A phase II study of selumetinib in recurrent endometrial cancer reported very limited clinical activity, with an objective response rate of 6% (3 of 52 patients) and median PFS of 2.3 months (18).”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The proof and measurement of association between two things
Spearman, C. (1904) · The American Journal of Psychology · doi:10.2307/1412159 · Cited by 8,039
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
Research works printed but not linked: 22
- Jemal, 2008, Cancer statistics, 2008, CA Cancer J. Clin., 58, 71, 10.3322/CA.2007.0010 · DOI · Paper page
- Ahn, 2001, Pharmacologic inhibitors of MKK1 and MKK2, Methods Enzymol., 332, 417, 10.1016/S0076-6879(01)32219-X · DOI
- Lewis, 2000, Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry, Mol. Cell, 6, 1343, 10.1016/S1097-2765(00)00132-5 · DOI · Paper page
- Yeh, 2007, Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor, Clin. Cancer Res., 13, 1576, 10.1158/1078-0432.CCR-06-1150 · DOI · Paper page
- Farley, 2013, Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study, Lancet Oncol., 14, 134, 10.1016/S1470-2045(12)70572-7 · DOI · Paper page
- Bell, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
- Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst., 92, 205, 10.1093/jnci/92.3.205 · DOI · Paper page
- Aghajanian, 2011, Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study, J. Clin. Oncol., 29, 2259, 10.1200/JCO.2010.32.6397 · DOI · Paper page
- Kaplan, 1958, Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc., 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
- Mehta, 1983, A network algorithm for performing fisher's exact test in r x c contingency tables, J. Am. Stat. Assoc., 78, 427
- Cox, 1972, Regression models and life tables, J. R. Stat. Soc. Ser. B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
- Naz, 2012, Regulation of S100A2 expression by TGF-beta-induced MEK/ERK signalling and its role in cell migration/invasion, Biochem. J., 447, 81, 10.1042/BJ20120014 · DOI
- Jing, 2012, Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212, Mol. Cancer Ther., 11, 720, 10.1158/1535-7163.MCT-11-0505 · DOI · Paper page
- Ventura, 2010, Activation of the MEK-S6 pathway in high-grade ovarian cancers, Appl. Immunohistochem. Mol. Morphol., 18, 499, 10.1097/PAI.0b013e3181e53e1c · DOI
- Meng, 2009, High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886), Cancer Biol. Ther., 8, 2073, 10.4161/cbt.8.21.9844 · DOI
- Sebolt-Leopold, 2003, Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition, Methods Mol. Med., 85, 31
- Pavlidou, 2014, Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer, ScientificWorldJournal, 709736
- Oza, 2011, A randomized phase II (RP2) trial of ridaforolimus (r) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma, Proc. Am. Soc. Clin. Oncol., 29
- Fleming, 2014, Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A Gynecologic Oncology Group study, Gynecol. Oncol., 132, 585, 10.1016/j.ygyno.2014.01.015 · DOI
- Myers, 2013, Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC), J. Clin. Oncol., 31, 10.1200/jco.2013.31.15_suppl.5524 · doi:10.1200/jco.2013.31.15_suppl.5524
- Gonzalez-Billalabeitia, 2014, Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition, Cancer Discov., 8, 896, 10.1158/2159-8290.CD-13-0230 · DOI · Paper page
- Mendes-Pereira, 2009, Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors, EMBO Mol. Med., 1, 315, 10.1002/emmm.200900041 · DOI · Paper page
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
Molecular Genetics of Endometrial Carcinoma
Bell, D. W., & Ellenson, L. H. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043609 · Cited by 304
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
Ocular Adverse Events Associated with Mek Inhibitors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117
Metadata
- Authors
- Coleman, R. L., Sill, M. W., Thaker, P. H., Bender, D. P., Street, D., McGuire, W. P., Johnston, C. M., & Rotmensch, J.
- Venue
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 138
- Issue
- 1
- Pages
- 30-35
- ISSN
- 0090-8258
- Cited by
- 64
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- National Cancer Institute (1 U10 CA180822, CA 27469, CA 37517)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. https://app.cochat.ai/papers/10.1016/j.ygyno.2015.04.005
- The paper
- Coleman, R. L., Sill, M. W., Thaker, P. H., Bender, D. P., Street, D., McGuire, W. P., Johnston, C. M., & Rotmensch, J. (2015). A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2015.04.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.